BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 26748161)

  • 1. Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Aoki T; Koh K; Kawano Y; Mori M; Arakawa Y; Kato M; Hanada R
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):771-775. PubMed ID: 26748161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high.
    Blennow O; Fjaertoft G; Winiarski J; Ljungman P; Mattsson J; Remberger M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1646-9. PubMed ID: 24914821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
    Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients.
    Issa NC; Marty FM; Leblebjian H; Galar A; Shea MM; Antin JH; Soiffer RJ; Baden LR
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):285-7. PubMed ID: 24269706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation.
    Sasadeusz J; Prince HM; Schwarer A; Szer J; Stork A; Bock HL; Povey M; Nicholson O; Innis BL
    Transpl Infect Dis; 2014 Dec; 16(6):1024-31. PubMed ID: 25272081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
    Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients.
    Chun JY; Kim K; Lee MK; Kang CK; Koh Y; Shin DY; Hong J; Choe PG; Kim NJ; Yoon SS; Park WB; Kim I; Oh MD
    BMC Infect Dis; 2021 Jan; 21(1):117. PubMed ID: 33499826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety profile of varicella vaccine: a 10-year review.
    Galea SA; Sweet A; Beninger P; Steinberg SP; Larussa PS; Gershon AA; Sharrar RG
    J Infect Dis; 2008 Mar; 197 Suppl 2():S165-9. PubMed ID: 18419392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allotype analysis to distinguish the origin of varicella-zoster virus immunoglobulin G after allogeneic stem cell transplantation.
    Yamazaki R; Nakasone H; Tanaka Y; Sato M; Terasako K; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Ashizawa M; Machishima T; Kimura S; Kikuchi M; Okuda S; Kako S; Kanda J; Tanihara A; Nishida J; Kanda Y
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1013-20. PubMed ID: 23583826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
    Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.
    Boeckh M; Kim HW; Flowers ME; Meyers JD; Bowden RA
    Blood; 2006 Mar; 107(5):1800-5. PubMed ID: 16282339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation.
    Leung TF; Chik KW; Li CK; Lai H; Shing MM; Chan PK; Lee V; Yuen PM
    Bone Marrow Transplant; 2000 Jan; 25(2):167-72. PubMed ID: 10673675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of vaccinating sibling donors with live-attenuated varicella zoster vaccine before hematopoietic stem cell transplantation.
    Leung AY; Chow HC; Kwok JS; Lui CK; Cheng VC; Yuen KY; Lie AK; Liang R
    Bone Marrow Transplant; 2007 Jun; 39(11):661-5. PubMed ID: 17417658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study.
    Ljungman P; Wang FZ; Nilsson C; Solheim V; Linde A
    Support Care Cancer; 2003 Nov; 11(11):739-41. PubMed ID: 13680325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT).
    Chou JF; Kernan NA; Prockop S; Heller G; Scaradavou A; Kobos R; Knowles MA; Papadopoulos EB; Casson A; Copeland C; Torok-Castanza J; Zakak N; Ruggiero J; Small TN
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1708-13. PubMed ID: 21664979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients.
    Onozawa M; Hashino S; Takahata M; Fujisawa F; Kawamura T; Nakagawa M; Kahata K; Kondo T; Ota S; Tanaka J; Imamura M; Asaka M
    J Clin Microbiol; 2006 Dec; 44(12):4441-3. PubMed ID: 17035500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants.
    Hata A; Asanuma H; Rinki M; Sharp M; Wong RM; Blume K; Arvin AM
    N Engl J Med; 2002 Jul; 347(1):26-34. PubMed ID: 12097537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies.
    Parrino J; McNeil SA; Lawrence SJ; Kimby E; Pagnoni MF; Stek JE; Zhao Y; Chan IS; Kaplan SS
    Vaccine; 2017 Mar; 35(14):1764-1769. PubMed ID: 28268074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009.
    Weinmann S; Chun C; Schmid DS; Roberts M; Vandermeer M; Riedlinger K; Bialek SR; Marin M
    J Infect Dis; 2013 Dec; 208(11):1859-68. PubMed ID: 23922376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial.
    Trannoy E; Berger R; Holländer G; Bailleux F; Heimendinger P; Vuillier D; Creusvaux H
    Vaccine; 2000 Feb; 18(16):1700-6. PubMed ID: 10689152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.